Timeline
Avacta
FDA clears single pivotal trial path for Avacta's AVA6000 in salivary gland cancer
Avacta starts dosing patients in AVA6103 trial with cash runway extended to early 2027
Avacta Group raises £9m to repay debt
Avacta reports positive results in salivary gland cancer research
Avacta names Richard Hughes as non‑executive chairman
Avacta says pre|CISION releases payload faster and more selectively than approved ADCs
Avacta demonstrates AVA6103 outdelivers Enhertu and reveals dual‑payload in vivo data
Avacta to raise c.£10m via equity placing
More in Biotech
GENinCode genetic test cuts cardiac risk in Catalonia pilot
A real-world pilot by Catalonia's health service found GENinCode's CARDIO inCode-Score reclassified risk in over 40% of moderate-risk patients and drove measurable improvements in cholesterol and smoking cessation.